Lyell Immunopharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Lyell Immunopharma, Inc. (LYEL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $36.96 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-03-12
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $5.57, a 15.35% decline year-over-year.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $6.58, a 19.42% increase year-over-year.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2022-03-31 was $5.51.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $36.96, a 498.06% increase from fiscal 2024.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $6.18, a 22.86% increase from fiscal 2023.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $5.03, a 19.90% decline from fiscal 2022.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $6.28, a 49.88% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $36.96 10-K · filed 2026-03-12 | |||
| 2024-12-31 | $6.18 10-K · filed 2025-03-11 | |||
| 2024-09-30 | $6.71 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $6.74 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $5.57 10-Q · filed 2024-05-06 | |||
| 2023-12-31 | $5.03 10-K · filed 2024-02-28 | |||
| 2023-09-30 | $5.26 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $5.12 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $6.58 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $6.28 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $6.07 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $5.72 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $5.51 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $4.19 10-K · filed 2022-03-29 | |||
| 2021-09-30 | $4.00 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $3.83 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |